COMPANY

Aphios Corporation

HQ: North Reading, MA source · aphios.com ↗

Keywords: drug delivery neurology infectious disease infectious diseases disease by infectious agent Dementia Alzheimer Disease 1 Alzheimer Disease 2 Alzheimer Disease 3 Addiction Opioid Dependence Opioid Withdrawal APH-1105 APH-1501

Location: North Reading, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Oct 23, 2025 Grant Government grant announced Oct 23, 2025. Source: company's own press page. source ↗
Aug 28, 2025 Grant Government grant — SBIR: $416,134 (annual award, as published), announced Aug 28, 2025. Agency: NIH/NCCIH. Source: government award database. source ↗
Dec 12, 2024 Grant Government grant announced Dec 12, 2024. Source: company's own press page. source ↗
2023-10 Trial start Phase 2: Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction source ↗
2023-06 Trial start Phase 2: Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease source ↗

Funding

Last 2 years.

Oct 23, 2025 Government grant announced Oct 23, 2025. Source: company's own press page. source ↗
Aug 28, 2025 Government grant — SBIR: $416,134 (annual award, as published), announced Aug 28, 2025. Agency: NIH/NCCIH. Source: government award database. source ↗
Dec 12, 2024 Government grant announced Dec 12, 2024. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT03806478	Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease	Phase 2	Unknown status (ClinicalTrials.gov)	2023-06	2024-09 (estimated)
NCT03813095	Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction	Phase 2	Unknown status (ClinicalTrials.gov)	2023-10	2025-09 (estimated)